ʻO Semaglutide kahi lāʻau hoʻohaʻahaʻa glucose i hoʻomohala ʻia e Novo Nordisk no ka mālama ʻana i ka maʻi diabetes type 2. I Iune 2021, ua ʻae ka FDA iā Semaglutide no ke kūʻai ʻana ma ke ʻano he lāʻau hoʻemi kaumaha (inoa kālepa ʻo Wegovy). ʻO ka lāʻau lapaʻau he glucagon-like peptide 1 (GLP-1) receptor agonist hiki ke hoʻohālikelike i kona hopena, hoʻemi i ka pōloli, a pēlā e hoʻemi ai i ka ʻai a me ka calorie intake, no laila maikaʻi ia i ka pohō kaumaha.
Ma waho aʻe o ka hoʻohana ʻia e mālama i ka maʻi maʻi type 2 a me ka momona, ua ʻike ʻia ʻo Semaglutide e pale i ke olakino cardiovascular, hoʻemi i ka maʻi kanesa, a kōkua i ka haʻalele ʻana i ka inu. Eia kekahi, ua hōʻike ʻia ʻelua mau haʻawina hou e hiki ai iā Semaglutide ke hōʻemi i ka hopena o ka maʻi maʻi maʻi a me ka maʻi Alzheimer.
Ua hōʻike ʻia nā haʻawina mua e hiki i ka pohō kaumaha ke hoʻomaha i nā hōʻailona o ka osteoarthritis kuli (me ka hoʻomaha ʻeha). Eia nō naʻe, ʻaʻole i aʻo piha ʻia nā hopena o ka GLP-1 receptor agonist weight loss drugs e like me Semaglutide i nā hopena o ka osteoarthritis kuli i ka poʻe momona.
Ma ʻOkakopa 30, 2024, ua paʻi nā mea noiʻi mai ke Kulanui o Copenhagen a me Novo Nordisk i kahi pepa noiʻi i kapa ʻia ʻo: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis in the New England Journal of Medicine (NEJM), he puke pai lāʻau lapaʻau honua.
Ua hōʻike ʻia kēia noiʻi lapaʻau e hiki i ka semaglutide ke hōʻemi nui i ke kaumaha a hoʻemi nui i ka ʻeha i hoʻokumu ʻia e ka obesity-related knee arthritis (ʻo ka hopena analgesic e like me ka opioids), a hoʻomaikaʻi i ko lākou hiki ke komo i nā haʻuki. ʻO kēia hoʻi ka manawa mua i hōʻoia ʻia kahi ʻano hou o ka lāʻau hoʻemi kaumaha, he agonist receptor GLP-1, e mālama i ka maʻi arthritis.
Ka manawa hoʻouna: Feb-27-2025